CA2463158C - Depot formulations of iloperidone and a star polymer - Google Patents
Depot formulations of iloperidone and a star polymer Download PDFInfo
- Publication number
- CA2463158C CA2463158C CA2463158A CA2463158A CA2463158C CA 2463158 C CA2463158 C CA 2463158C CA 2463158 A CA2463158 A CA 2463158A CA 2463158 A CA2463158 A CA 2463158A CA 2463158 C CA2463158 C CA 2463158C
- Authority
- CA
- Canada
- Prior art keywords
- iloperidone
- intramuscular
- depot formulation
- formulation
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Abstract
This present invention relates to pharmaceutical compositions, in particular to depot formulations comprising iloperidone as active agent and a biodegradable, biocompatible polymer, as well as a process for preparing microparticle depot formulations.
Description
DEPOT FORMULATIONS OF ILOPERIDONE AND A STAR POLYMER
This present invention relates to pharmaceutical compositions, in particular to depot formulations comprising iloperidone as active agent and a biodegradable, biocompatible polymer, as well as a process for preparing microparticle depot formulations.
Iloperidone is 1444344-(6-fluoro-1,2-benzisoxazol-3-y1)-1 -piperidinyl]propoxy]-3-methoxyphenyliethanone. As used herein, "iloperidone" includes any pharmaceutically acceptable salts, hydrates, solvates, and/or stereoisomers thereof, and any metabolites thereof, including any salts, hydrates, solvates and/or stereoisomers of such metabolites.
U.S. Patent No. 5,364,866 describes that the compound iloperidone is useful as an anti-= psychotic and analgesic agent. U.S. Patent No. 5,955,459 describes compositions for treating schizophrenia containing conjugates of a fatty acid and iloperidone.
The present inventors have found depot formulations comprising iloperidone entrapped in a biodegradable, biocompatible polymer, preferably a star polymer, e.g. poly(d,l-lactide-co-glycolide). Accordingly the present invention provides a controlled-release of iloperidone over, e.g., 2-6 weeks with such depot formulations.
la According to one aspect of the present invention, there is provided an intramuscular or subcutaneous injectable depot formulation comprising iloperidone and a biodegradable, biocompatible polymer, wherein the amount of iloperidone in the formulation is from 50 to 90 weight percent based upon weight of the formulation, and wherein the polymer is a polylactide-co-glycolide.
According to another aspect of the present invention, there is provided an injectable microparticle comprising iloperidone and a biodegradable, biocompatible star polymer, wherein the amount of iloperidone is from 50 to 90 weight percent, based on weight of the microparticle, and wherein the polymer is a polylactide-co-glycolide.
According to yet another aspect of the present invention, there is provided a process for preparing an injectable microparticle comprising iloperidone and a biodegradable, biocompatible star polymer, wherein the polymer is a polylactide-co-glycolide ester of a polyol, wherein the amount of iloperidone is from 50 to 90 weight percent based on weight of the microparticle, said process comprising: i) dissolving the polymer and iloperidone in an organic solvent, ii) mixing an aqueous solution of a surfactant and a buffer, iii) mixing the solution of step i) and step ii) using a static mixer to form an emulsion, iv) optionally heating the emulsion at an elevated temperature, v) collecting the generated microparticles by sedimentation, vi) optionally washing the microparticles, and vii) drying the microparticles under vacuum.
According to still another aspect of the present invention, there is provided a commercial package comprising the depot formulation described herein and instructions for the use thereof for treating schizophrenia in a patient.
According to a further aspect of the present invention, there is provided an intramuscular or subcutaneous injectable depot formulation comprising iloperidone and a biodegradable, biocompatible star polymer, wherein the polymer is a polylactide-co-glycolide ester of a polyol, and wherein the amount of iloperidone in the formulation is from 50 to 80 weight percent based upon weight of the formulation.
lb The depot formulations of the present invention comprising iloperidone and a biodegradable, biocompatible polymer may be in the form of microparticles.
As used herein, "biocompatible" means that the polymer is not toxic to the human body, is pharmaceutically acceptable, and is not carcinogenic. As used herein, "biodegradable" means a material that should degrade by bodily processes to products readily disposable by the body and should not accumulate in the body.
Suitable star polymers, used by the present invention are typically branched polyesters. As used herein "star polymer" is understood to mean that the structure of the polyester is star-shaped. These polyesters have a single polyol residue as a central moiety surrounded by acid residue chains. The polyol moiety may be, e.g., glucose or, e.g., mannitol. These esters are known and described in GB 2,145,422 and in U.S. Patent No. 5,538,739.
This present invention relates to pharmaceutical compositions, in particular to depot formulations comprising iloperidone as active agent and a biodegradable, biocompatible polymer, as well as a process for preparing microparticle depot formulations.
Iloperidone is 1444344-(6-fluoro-1,2-benzisoxazol-3-y1)-1 -piperidinyl]propoxy]-3-methoxyphenyliethanone. As used herein, "iloperidone" includes any pharmaceutically acceptable salts, hydrates, solvates, and/or stereoisomers thereof, and any metabolites thereof, including any salts, hydrates, solvates and/or stereoisomers of such metabolites.
U.S. Patent No. 5,364,866 describes that the compound iloperidone is useful as an anti-= psychotic and analgesic agent. U.S. Patent No. 5,955,459 describes compositions for treating schizophrenia containing conjugates of a fatty acid and iloperidone.
The present inventors have found depot formulations comprising iloperidone entrapped in a biodegradable, biocompatible polymer, preferably a star polymer, e.g. poly(d,l-lactide-co-glycolide). Accordingly the present invention provides a controlled-release of iloperidone over, e.g., 2-6 weeks with such depot formulations.
la According to one aspect of the present invention, there is provided an intramuscular or subcutaneous injectable depot formulation comprising iloperidone and a biodegradable, biocompatible polymer, wherein the amount of iloperidone in the formulation is from 50 to 90 weight percent based upon weight of the formulation, and wherein the polymer is a polylactide-co-glycolide.
According to another aspect of the present invention, there is provided an injectable microparticle comprising iloperidone and a biodegradable, biocompatible star polymer, wherein the amount of iloperidone is from 50 to 90 weight percent, based on weight of the microparticle, and wherein the polymer is a polylactide-co-glycolide.
According to yet another aspect of the present invention, there is provided a process for preparing an injectable microparticle comprising iloperidone and a biodegradable, biocompatible star polymer, wherein the polymer is a polylactide-co-glycolide ester of a polyol, wherein the amount of iloperidone is from 50 to 90 weight percent based on weight of the microparticle, said process comprising: i) dissolving the polymer and iloperidone in an organic solvent, ii) mixing an aqueous solution of a surfactant and a buffer, iii) mixing the solution of step i) and step ii) using a static mixer to form an emulsion, iv) optionally heating the emulsion at an elevated temperature, v) collecting the generated microparticles by sedimentation, vi) optionally washing the microparticles, and vii) drying the microparticles under vacuum.
According to still another aspect of the present invention, there is provided a commercial package comprising the depot formulation described herein and instructions for the use thereof for treating schizophrenia in a patient.
According to a further aspect of the present invention, there is provided an intramuscular or subcutaneous injectable depot formulation comprising iloperidone and a biodegradable, biocompatible star polymer, wherein the polymer is a polylactide-co-glycolide ester of a polyol, and wherein the amount of iloperidone in the formulation is from 50 to 80 weight percent based upon weight of the formulation.
lb The depot formulations of the present invention comprising iloperidone and a biodegradable, biocompatible polymer may be in the form of microparticles.
As used herein, "biocompatible" means that the polymer is not toxic to the human body, is pharmaceutically acceptable, and is not carcinogenic. As used herein, "biodegradable" means a material that should degrade by bodily processes to products readily disposable by the body and should not accumulate in the body.
Suitable star polymers, used by the present invention are typically branched polyesters. As used herein "star polymer" is understood to mean that the structure of the polyester is star-shaped. These polyesters have a single polyol residue as a central moiety surrounded by acid residue chains. The polyol moiety may be, e.g., glucose or, e.g., mannitol. These esters are known and described in GB 2,145,422 and in U.S. Patent No. 5,538,739.
- 2 -The star polymers may be prepared using polyhydroxy compounds, e.g., polyol, e.g., glucose or mannitol as the initiator. The polyol contains at least 3 hydroxy groups and has a molecular weight of up to about 20,000 Daltons, with at least 1, preferably at least 2, e.g., as a mean 3 of the hydroxy groups of the polyol being in the form of ester groups, which contain polylactide or co-polylactide chains. Typically 0.2% glucose is used to initiate polymerization. The branched polyesters, e.g., poly(d,l-lactide-co-glycolide) have a central glucose moiety having rays of linear polylactide chains. The preferred polyester chains in the star polymer compounds preferably used according to the invention are co-polymers of the alpha carboxylic acid moieties, lactic acid and glycolic acid, or of the lactone dimers. The molar ratio of lactide: glycolide may be from about 75:25 to 25:75, e.g., 60:40 to 40:60, with from 55:45 to 45:55, e.g., 55:45 to 50:50 more preferred.
The branched polyesters, e.g., poly(d,l-lactide-co-glycolide) having a central glucose moiety having rays of linear polylactide chains preferably have an average molecular weight (Mõ) in the range of from about 10,000 to 200,000 Daltons, preferably 25,000 to 100,000 Daltons, especially 35,000 to 60,000 Daltons and a polydispersity, e.g., of from 1.7 to
The branched polyesters, e.g., poly(d,l-lactide-co-glycolide) having a central glucose moiety having rays of linear polylactide chains preferably have an average molecular weight (Mõ) in the range of from about 10,000 to 200,000 Daltons, preferably 25,000 to 100,000 Daltons, especially 35,000 to 60,000 Daltons and a polydispersity, e.g., of from 1.7 to
3.0, e.g., 2.0 to 2.5. The intrinsic viscosities of star polymers of Mõ 35,000 and Mõ 60,000 are 0.36 and 0.51 dl/g, respectively, in chloroform. E.g. a star polymer having a M,, 52,000 has a viscosity of 0.475 dl/g in chloroform.
The terms microsphere, microcapsule and microparticle are considered to be interchangeable with respect to the invention, and denote the encapsulation of the active agent by the polymer, preferably with the active agent distributed throughout the polymer, which is then a matrix for the active agent. In that case preferably the terms microsphere or more generally microparticle are used.
The amount of iloperidone incorporated in the implants or microparticles is from about 1 to about 90 weight percent, based on the total weight of the implant or microparticle.
Preferably, the amount of iloperidone incorporated in the implants or microparticles is from 50 to 80 weight percent, more preferably 60 to 75 weight percent.
In one embodiment of this invention, the microparticles contain further excipients such as surfactants or solvents, e.g., solid solvents. Such excipients may accelerate or further retard the release of the active agent.
The components of the compositions of the invention are e.g. described in Fiedler, H.P.
"Lexikon der Hilfsstoffe für Pharmazie, Kosmetik und angrenzende Gebiete", Editio Cantor Verlag Aulendorf, Aulendorf, 4th revised and expanded edition (1996) .
=
The microparticles of the current invention are usually made up of particles of a spherical shape, although microparticles may be irregularly shaped. They may exhibit a smooth to rough surface and can be dense or porous like. The microparticles have an average particle size from 3 to 300 microns, preferably from 10 to 200 microns, more preferably from 10 to 100 microns.
According to another aspect the invention provides a process for preparing microparticles comprising iloperidone or a pharmaceutically acceptable salt thereof and a biodegradable, biocompatible star polymer. The microparticles may be manufactured by several processes, e.g., coacervation, e.g., spray drying or, e.g., solvent evaporation. Solvent evaporation is a preferred process, which comprises the following steps:
i) dissolving the polymer and iloperidone in an organic solvent, e.g., methylene chloride, ii) mixing an aqueous solution of a surfactant, e.g., polyvinyl alcohol, and a buffer, e.g., disodium hydrogen phosphate, iii) mixing the solution of step i) and step ii) using a static mixer to form an emulsion, iv) optionally heating the emulsion to an elevated temperature, e.g., between about 30 to about 60 C, preferably between 40 C and 50 C, v) collecting the generated microparticles by sedimentation, vi) optionally washing the microparticles, and vii) drying the microparticles under vacuum.
The ratio of the solutions i) and ii) combined in step iii) may be from 1:20 to 5:1, preferably from 1:20 to 1:5.
A variety of solvents may be used for the internal phase such as halogenated and/or aliphatic or aromatic hydrocarbons as well as mixtures of those with a water miscible liquid.
Preferably the solvent is methylene chloride.
=
The terms microsphere, microcapsule and microparticle are considered to be interchangeable with respect to the invention, and denote the encapsulation of the active agent by the polymer, preferably with the active agent distributed throughout the polymer, which is then a matrix for the active agent. In that case preferably the terms microsphere or more generally microparticle are used.
The amount of iloperidone incorporated in the implants or microparticles is from about 1 to about 90 weight percent, based on the total weight of the implant or microparticle.
Preferably, the amount of iloperidone incorporated in the implants or microparticles is from 50 to 80 weight percent, more preferably 60 to 75 weight percent.
In one embodiment of this invention, the microparticles contain further excipients such as surfactants or solvents, e.g., solid solvents. Such excipients may accelerate or further retard the release of the active agent.
The components of the compositions of the invention are e.g. described in Fiedler, H.P.
"Lexikon der Hilfsstoffe für Pharmazie, Kosmetik und angrenzende Gebiete", Editio Cantor Verlag Aulendorf, Aulendorf, 4th revised and expanded edition (1996) .
=
The microparticles of the current invention are usually made up of particles of a spherical shape, although microparticles may be irregularly shaped. They may exhibit a smooth to rough surface and can be dense or porous like. The microparticles have an average particle size from 3 to 300 microns, preferably from 10 to 200 microns, more preferably from 10 to 100 microns.
According to another aspect the invention provides a process for preparing microparticles comprising iloperidone or a pharmaceutically acceptable salt thereof and a biodegradable, biocompatible star polymer. The microparticles may be manufactured by several processes, e.g., coacervation, e.g., spray drying or, e.g., solvent evaporation. Solvent evaporation is a preferred process, which comprises the following steps:
i) dissolving the polymer and iloperidone in an organic solvent, e.g., methylene chloride, ii) mixing an aqueous solution of a surfactant, e.g., polyvinyl alcohol, and a buffer, e.g., disodium hydrogen phosphate, iii) mixing the solution of step i) and step ii) using a static mixer to form an emulsion, iv) optionally heating the emulsion to an elevated temperature, e.g., between about 30 to about 60 C, preferably between 40 C and 50 C, v) collecting the generated microparticles by sedimentation, vi) optionally washing the microparticles, and vii) drying the microparticles under vacuum.
The ratio of the solutions i) and ii) combined in step iii) may be from 1:20 to 5:1, preferably from 1:20 to 1:5.
A variety of solvents may be used for the internal phase such as halogenated and/or aliphatic or aromatic hydrocarbons as well as mixtures of those with a water miscible liquid.
Preferably the solvent is methylene chloride.
=
- 4 -As surfactants in the external phase may be used poly(vinyl alcohol), carboxymethyl cellulose, gelatin, poly(vinyl pyrrolidone), polyoxyethylene 20 sorbitan monooleate and polyoxyethylene 20 sorbitan monolaurate.
The microparticles of the present invention are useful for the treatment of central nervous system disorders, e.g., psychotic disorders, e.g., schizophrenia, or, e.g., as analgesics.
The depot formulations of microparticles of the invention may be administered by intramuscular or subcutaneous injection. Depot formulations of this invention administered by injection provide an effective treatment of diseases over an extended period, e.g., over 2 to 6 weeks. The microparticles allow a controlled release of iloperidone by diffusion and therefore steady-state levels of the drug are obtained over the extended period.
The exact amount of active agent entrapped in the polymer, i.e., the exact amount of depot formulation, e.g., microparticles formulation, to be administered depends on a number of factors, e.g., the condition to be treated, the desired duration of treatment, the rate of release of active agent and the degradability of the polymeric matrix. The amount of active agent required may be determined on the basis of known in vitro or in vivo techniques.
Repeated administration of the depot formulation of the invention may be effected when the drug is sufficiently released.
Dosages required in practicing the method of the present invention will vary depending upon, e.g., the mode of administration and the severity of the condition to be treated. Large amount of active agent, e.g., up to 750 or 1000 mg of active agent, e.g., in form of a suspension, may be administered in a single administration, e.g., in one injection.
Microparticles prepared by the process of the present invention are stored in the form of a powder. For administration as injection the microparticles are suspended in a suitable vehicle.
Filling may be effected before or after sterilization of the depot formulation. Sterilization of the formulation of the present invention and the primary package can be effected, e.g., by gamma irradiation, e.g., at an energy of 25-35 kGy, without degradation of active agent and/or microparticles.
The following examples illustrate the invention.
The microparticles of the present invention are useful for the treatment of central nervous system disorders, e.g., psychotic disorders, e.g., schizophrenia, or, e.g., as analgesics.
The depot formulations of microparticles of the invention may be administered by intramuscular or subcutaneous injection. Depot formulations of this invention administered by injection provide an effective treatment of diseases over an extended period, e.g., over 2 to 6 weeks. The microparticles allow a controlled release of iloperidone by diffusion and therefore steady-state levels of the drug are obtained over the extended period.
The exact amount of active agent entrapped in the polymer, i.e., the exact amount of depot formulation, e.g., microparticles formulation, to be administered depends on a number of factors, e.g., the condition to be treated, the desired duration of treatment, the rate of release of active agent and the degradability of the polymeric matrix. The amount of active agent required may be determined on the basis of known in vitro or in vivo techniques.
Repeated administration of the depot formulation of the invention may be effected when the drug is sufficiently released.
Dosages required in practicing the method of the present invention will vary depending upon, e.g., the mode of administration and the severity of the condition to be treated. Large amount of active agent, e.g., up to 750 or 1000 mg of active agent, e.g., in form of a suspension, may be administered in a single administration, e.g., in one injection.
Microparticles prepared by the process of the present invention are stored in the form of a powder. For administration as injection the microparticles are suspended in a suitable vehicle.
Filling may be effected before or after sterilization of the depot formulation. Sterilization of the formulation of the present invention and the primary package can be effected, e.g., by gamma irradiation, e.g., at an energy of 25-35 kGy, without degradation of active agent and/or microparticles.
The following examples illustrate the invention.
- 5 -Examples 1 to 4: Microparticles with Drug Loadings 20 to 75 Weight Percent Ex. 1 Ex. 2 Ex. 3 Ex. 4 Drug loading Drug loading Drug loading Drug loading 20% 30% 60% 75%
Internal phase Iloperidone 1.6 g 90 g 7 g 67.5 g poly(d,1,-lactide- 6.4 g 210 g 4.8 g 22.5 g co-glycolide) CH2C12 21.3 ml 630 ml 30 ml 144 ml External phase polyvinyl alcohol 25 g 119.7 g 25 g Na2HPO4 4.7 g 75.5 g 47.3 g Water for II 81 51 injection Solution in vessel polyvinyl alcohol 337.5 g 150 g 425 g Na2HPO4 213g 28.4g 268g Water for 68 1 6 1 85 I
injection Static mixer DN2, 20 DN6, 14 DN6, 14 Elements Elements Elements The internal phase is prepared by dissolving Iloperidone and the poly(d,1,-lactide-co-glycolide) in methylene chloride. A polyvinyl alcohol in water solution with disodium hydrogen phosphate (Na2HPO4) is prepared (external phase).
The solutions (internal phase and external phase) are filtered and pumped through a static mixer (Ex 1,2,4) into a stirred vessel containing a solution of polyvinyl alcohol and disodium hydrogen phosphate in water (Ex 2-4) . The resulting solution is heated to 40 C- 45 C under stirring within 90 min. After cooling the suspension is allowed to sediment for 20 min. The aqueous supernatand is removed under vacuo. Optionally the microparticles are re-suspended again in aqueous disodium hydrogen phosphate solution and treated as above (heating, cooling, sedimentation, removal of the supernatant). The microparticles are washed with water for approximately 30 min. After sedimentation for 20 min, the solution is removed and the microparticles are filtered through an Ultipor filter, washed with water and dried under vacuum. The so obtained microparticles are determined to have an average
Internal phase Iloperidone 1.6 g 90 g 7 g 67.5 g poly(d,1,-lactide- 6.4 g 210 g 4.8 g 22.5 g co-glycolide) CH2C12 21.3 ml 630 ml 30 ml 144 ml External phase polyvinyl alcohol 25 g 119.7 g 25 g Na2HPO4 4.7 g 75.5 g 47.3 g Water for II 81 51 injection Solution in vessel polyvinyl alcohol 337.5 g 150 g 425 g Na2HPO4 213g 28.4g 268g Water for 68 1 6 1 85 I
injection Static mixer DN2, 20 DN6, 14 DN6, 14 Elements Elements Elements The internal phase is prepared by dissolving Iloperidone and the poly(d,1,-lactide-co-glycolide) in methylene chloride. A polyvinyl alcohol in water solution with disodium hydrogen phosphate (Na2HPO4) is prepared (external phase).
The solutions (internal phase and external phase) are filtered and pumped through a static mixer (Ex 1,2,4) into a stirred vessel containing a solution of polyvinyl alcohol and disodium hydrogen phosphate in water (Ex 2-4) . The resulting solution is heated to 40 C- 45 C under stirring within 90 min. After cooling the suspension is allowed to sediment for 20 min. The aqueous supernatand is removed under vacuo. Optionally the microparticles are re-suspended again in aqueous disodium hydrogen phosphate solution and treated as above (heating, cooling, sedimentation, removal of the supernatant). The microparticles are washed with water for approximately 30 min. After sedimentation for 20 min, the solution is removed and the microparticles are filtered through an Ultipor filter, washed with water and dried under vacuum. The so obtained microparticles are determined to have an average
6 particle size of 50-150 microns. Above formulations show a sustained release of Iloperidone in the plasma over a period of over 2 weeks in animals and humans.
The scope of the claims should not be limited by the preferred embodiments set forth in the examples, but should be given the broadest interpretation consistent with the description as a whole.
The scope of the claims should not be limited by the preferred embodiments set forth in the examples, but should be given the broadest interpretation consistent with the description as a whole.
Claims (25)
1. An intramuscular or subcutaneous injectable depot formulation comprising iloperidone and a biodegradable, biocompatible polymer, wherein the amount of iloperidone in the formulation is from 50 to 90 weight percent based upon weight of the formulation, and wherein the polymer is a polylactide-co-glycolide.
2. The intramuscular or subcutaneous injectable depot formulation of claim 1, wherein the polymer is a polylactide-co-glycolide ester of a polyol.
3. The intramuscular or subcutaneous injectable depot formulation of claim 1, wherein the polymer is a 40-60 to 60-40 polylactide-co-glycolide ester of a polyol, wherein the polyol is glucose.
4. The intramuscular or subcutaneous injectable depot formulation of any one of claims 1 to 3, which is in the form of microparticles.
5. The intramuscular or subcutaneous injectable depot formulation of claim 4, wherein the shape of the microparticles is spherical.
6. The intramuscular or subcutaneous injectable depot formulation of claim 4 or 5, wherein the microparticles are suspended in a suitable vehicle prior to injection.
7. The intramuscular or subcutaneous injectable depot formulation of any one of claims 1 to 6, wherein the iloperidone comprises from 50 to 80 weight percent of the formulation.
8. The intramuscular or subcutaneous injectable depot formulation of any one of claims 1 to 7, wherein the iloperidone comprises from 60 to 75 weight percent of the formulation.
9. The intramuscular or subcutaneous injectable depot formulation of any one of claims 1 to 8, which further comprises a surfactant.
10. The intramuscular or subcutaneous injectable depot formulation of any one of claims 1 to 9, which further comprises a solvent.
11. A package comprising a container containing the depot formulation as defined in any one of claims 1 to 10 and instructions for using the depot formulation for treating schizophrenia in a patient.
12. An injectable microparticle comprising iloperidone and a biodegradable, biocompatible star polymer, wherein the amount of iloperidone is from 50 to 90 weight percent, based on weight of the microparticle, and wherein the polymer is a polylactide-co-glycolide.
13. The injectable microparticle of claim 12, wherein the amount of iloperidone is from 50 to 80 weight percent based on the weight of the microparticle.
14. The injectable microparticle of claim 12, wherein the amount of iloperidone is from 60 to 75 weight percent based on the weight of the microparticle.
15. A process for preparing an injectable microparticle comprising iloperidone and a biodegradable, biocompatible star polymer, wherein the polymer is a polylactide-co-glycolide ester of a polyol, wherein the amount of iloperidone is from 50 to 90 weight percent based on weight of the microparticle, said process comprising:
i) dissolving the polymer and iloperidone in an organic solvent, ii) mixing an aqueous solution of a surfactant and a buffer, iii) mixing the solution of step i) and step ii) using a static mixer to form an emulsion, iv) optionally heating the emulsion at an elevated temperature, v) collecting the generated microparticles by sedimentation, vi) optionally washing the microparticles, and vii) drying the microparticles under vacuum.
i) dissolving the polymer and iloperidone in an organic solvent, ii) mixing an aqueous solution of a surfactant and a buffer, iii) mixing the solution of step i) and step ii) using a static mixer to form an emulsion, iv) optionally heating the emulsion at an elevated temperature, v) collecting the generated microparticles by sedimentation, vi) optionally washing the microparticles, and vii) drying the microparticles under vacuum.
16. The process of claim 15, wherein the amount of iloperidone is from 50 to 80 weight percent based on weight of the microparticle.
17. An intramuscular or subcutaneous injectable depot formulation comprising iloperidone and a biodegradable, biocompatible star polymer, wherein the polymer is a -co-glycolide ester of a polyol, and wherein the amount of iloperidone in the formulation is from 50 to 80 weight percent based upon weight of the formulation.
18. The intramuscular or subcutaneous injectable depot formulation of claim 17, wherein the polymer is a 40-60 to 60-40 polylactide-co-glycolide ester of a polyol.
19. The intramuscular or subcutaneous injectable depot formulation of any one of claims 17 to 18, which is in the form of microparticles.
20. The intramuscular or subcutaneous injectable depot formulation of claim 19, wherein the shape of the microparticles is spherical.
21. The intramuscular or subcutaneous injectable depot formulation of claim 19 or 20, wherein the microparticles are suspended in a suitable vehicle prior to injection.
22. The intramuscular or subcutaneous injectable depot formulation of any one of claims 17 to 21, wherein the iloperidone comprises from 60 to 75 weight percent of the formulation.
23. The intramuscular or subcutaneous injectable depot formulation of any one of claims 17 to 21, which further comprises a surfactant.
24. The intramuscular or subcutaneous injectable depot formulation of any one of claims 17 to 21, which further comprises a solvent.
25. A package comprising a container containing the depot formulation as defined in any one of claims 17 to 24 and instructions for using the depot formulation for treating schizophrenia in a patient.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33903601P | 2001-10-30 | 2001-10-30 | |
| US60/339,036 | 2001-10-30 | ||
| PCT/EP2002/012073 WO2003037337A1 (en) | 2001-10-30 | 2002-10-29 | Depot formulations of iloperidone and a star polymer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2463158A1 CA2463158A1 (en) | 2003-05-08 |
| CA2463158C true CA2463158C (en) | 2013-07-30 |
Family
ID=23327202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2463158A Expired - Lifetime CA2463158C (en) | 2001-10-30 | 2002-10-29 | Depot formulations of iloperidone and a star polymer |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7767230B2 (en) |
| EP (2) | EP2295058B1 (en) |
| JP (1) | JP5067998B2 (en) |
| CN (2) | CN101912367A (en) |
| AT (1) | ATE493129T1 (en) |
| BR (1) | BRPI0213564B8 (en) |
| CA (1) | CA2463158C (en) |
| CY (1) | CY1111357T1 (en) |
| DE (1) | DE60238780D1 (en) |
| ES (2) | ES2436439T3 (en) |
| HK (2) | HK1068263A1 (en) |
| WO (1) | WO2003037337A1 (en) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL148372A0 (en) * | 1999-09-09 | 2002-09-12 | Univ California | Cationic liposome delivery of taxanes to angiogenic blood vessels |
| WO2003037337A1 (en) * | 2001-10-30 | 2003-05-08 | Novartis Ag | Depot formulations of iloperidone and a star polymer |
| GB0216416D0 (en) * | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
| US20100063093A1 (en) | 2007-03-28 | 2010-03-11 | Curt Wolfgang | Methods for the administration of iloperidone |
| WO2006039663A2 (en) | 2004-09-30 | 2006-04-13 | Vanda Pharmaceuticals, Inc | Methods for the administration of iloperidone |
| ATE477291T1 (en) | 2005-10-25 | 2010-08-15 | Evonik Degussa Gmbh | PREPARATIONS COMPRISING HYPERBRANCHED POLYMERS |
| DE102005051342A1 (en) * | 2005-10-25 | 2007-04-26 | Goldschmidt Gmbh | Encapsulation and controlled release of biologically active drugs with enzymatically degradable hyperbranched carrier polymers |
| JP2009538331A (en) | 2006-05-22 | 2009-11-05 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | Treatment for depression disorders |
| CN100460441C (en) * | 2006-09-25 | 2009-02-11 | 南开大学 | Organism degradable star-type structure poly (glycolide-lactide) medicine carrier microsphere and preparation method thereof |
| WO2008054725A2 (en) | 2006-10-31 | 2008-05-08 | Surmodics Pharmaceuticals, Inc. | Spheronized polymer particles |
| CA2698534C (en) * | 2007-09-10 | 2018-10-09 | Vanda Pharmaceuticals, Inc. | Prediction of qt prolongation based on snp genotype |
| WO2009076664A1 (en) | 2007-12-13 | 2009-06-18 | Vanda Pharmaceuticals Inc. | Method and composition for treating a serotonin receptor-mediated condition |
| AU2008334932B2 (en) * | 2007-12-13 | 2014-05-22 | Vanda Pharmaceuticals Inc. | Method and composition for treating an alpha adrenoceptor-mediated condition |
| EP2453891A1 (en) | 2009-07-16 | 2012-05-23 | Vanda Pharmaceuticals Inc. | Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia |
| WO2011077239A2 (en) * | 2009-12-23 | 2011-06-30 | Lupin Limited | Slow release pharmaceutical compositions of iloperidone |
| CN102311430A (en) * | 2010-06-29 | 2012-01-11 | 大道隆达（北京）医药科技发展有限公司 | Novel crystalline state of iloperidone and preparation method thereof |
| WO2012123963A2 (en) * | 2011-02-24 | 2012-09-20 | Megafine Pharma (P) Ltd. | A process for preparation of iloperidone and amorphous co- precipitate of iloperidone with pharmaceutically acceptable excipient |
| KR102307012B1 (en) | 2012-01-26 | 2021-09-30 | 반다 파마슈티칼즈, 인코퍼레이티드. | Treatment of circadian rhythm disorders |
| US11918557B2 (en) | 2012-01-26 | 2024-03-05 | Vanda Pharmaceuticals Inc. | Treatment of circadian rhythm disorders |
| CN108997160A (en) | 2012-05-18 | 2018-12-14 | 万达制药公司 | (1R- is anti-)-N- [[2-(2,3- dihydro -4- benzofuranyl) cyclopropyl] methyl] propionamide metabolin |
| JP6144358B2 (en) | 2012-12-18 | 2017-06-07 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | Treatment of circadian rhythm disorders |
| US10376487B2 (en) | 2013-11-12 | 2019-08-13 | Vanda Pharmaceuticals Inc. | Method of treatment |
| US11090285B2 (en) | 2013-11-12 | 2021-08-17 | Vanda Pharmaceuticals Inc | Treatment of circadian rhythm disorders |
| CN103599074A (en) * | 2013-11-26 | 2014-02-26 | 重庆医药工业研究院有限责任公司 | Iloperidone sustained release microsphere and preparation method thereof |
| CN104352443A (en) * | 2014-10-21 | 2015-02-18 | 河北科技大学 | Iloperidone slow releasing microsphere and preparation method thereof |
| CN116211857A (en) | 2015-02-17 | 2023-06-06 | 万达制药公司 | Iloperidone for treating schizophrenia |
| US11071728B2 (en) | 2015-12-11 | 2021-07-27 | Vanda Pharmaceuticals Inc. | Treatment of schizophrenia |
| WO2020117901A1 (en) * | 2018-12-04 | 2020-06-11 | Vanda Pharmaceuticals Inc. | Depot administration of iloperidone |
| US11607408B2 (en) | 2019-10-15 | 2023-03-21 | Vanda Pharmaceuticals Inc. | Method of treatment of schizophrenia |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH656884A5 (en) * | 1983-08-26 | 1986-07-31 | Sandoz Ag | POLYOLESTERS, THEIR PRODUCTION AND USE. |
| DE3511587A1 (en) | 1985-03-27 | 1986-10-02 | Schering AG, Berlin und Bergkamen, 1000 Berlin | GLYCOESTER OF ESTRADIOL AND ESTRIOLS |
| US4886370A (en) | 1987-08-25 | 1989-12-12 | Nkk Corporation | Method for detecting a state of substance existing in pipe |
| US5364866A (en) | 1989-05-19 | 1994-11-15 | Hoechst-Roussel Pharmaceuticals, Inc. | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics |
| DK0402644T3 (en) * | 1989-05-19 | 1996-01-02 | Hoechst Roussel Pharma | N- (Aryloxyalkyl) heteroaryl piperidines and heteroaryl piperazines, process for their preparation and their use as medicaments |
| US5776963A (en) * | 1989-05-19 | 1998-07-07 | Hoechst Marion Roussel, Inc. | 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility |
| US5538739A (en) | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
| HUT63185A (en) | 1990-06-04 | 1993-07-28 | Schering Corp | Process for producing crystalline alpha-2-interferon |
| HU219487B (en) * | 1993-11-19 | 2001-04-28 | Janssen Pharmaceutica Nv. | Microparticles containing risperidone, process for producing them, their use, medicaments containing the same and their production |
| WO1998054186A1 (en) | 1997-05-26 | 1998-12-03 | Akzo Nobel N.V. | Salts of aromatic sulphonic acids |
| UA72189C2 (en) | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Aqueous suspensions of 9-hydroxy-risperidone fatty acid esters provided in submicron form |
| US5955459A (en) * | 1997-11-26 | 1999-09-21 | Neuromedica, Inc. | Fatty acid-antipsychotic compositions and uses thereof |
| US6541606B2 (en) | 1997-12-31 | 2003-04-01 | Altus Biologics Inc. | Stabilized protein crystals formulations containing them and methods of making them |
| DE19816070A1 (en) | 1998-04-09 | 1999-10-14 | Aventis Res & Tech Gmbh & Co | Prolonged-release tablet made from linear water-insoluble polysaccharides |
| WO2000023057A2 (en) * | 1998-10-16 | 2000-04-27 | Janssen Pharmaceutica N.V. | Atypical antiphsychotic in combination with acetylcholinesterase inhibitor for improving cognition |
| EP1290024A1 (en) | 2000-06-02 | 2003-03-12 | Novo Nordisk A/S | Glucose dependent release of insulin from glucose sensing insulin derivatives |
| WO2003020707A1 (en) | 2001-08-31 | 2003-03-13 | Novartis Ag | Optical isomers of an iloperidone metabolite |
| WO2003037337A1 (en) * | 2001-10-30 | 2003-05-08 | Novartis Ag | Depot formulations of iloperidone and a star polymer |
| GB0216416D0 (en) | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
-
2002
- 2002-10-29 WO PCT/EP2002/012073 patent/WO2003037337A1/en active Application Filing
- 2002-10-29 EP EP10009932.4A patent/EP2295058B1/en not_active Expired - Lifetime
- 2002-10-29 BR BRPI0213564A patent/BRPI0213564B8/en not_active IP Right Cessation
- 2002-10-29 ES ES10009932.4T patent/ES2436439T3/en not_active Expired - Lifetime
- 2002-10-29 JP JP2003539681A patent/JP5067998B2/en not_active Expired - Lifetime
- 2002-10-29 CN CN2010102694146A patent/CN101912367A/en active Pending
- 2002-10-29 CA CA2463158A patent/CA2463158C/en not_active Expired - Lifetime
- 2002-10-29 DE DE60238780T patent/DE60238780D1/en not_active Expired - Lifetime
- 2002-10-29 CN CNA028214269A patent/CN1578664A/en active Pending
- 2002-10-29 AT AT02785330T patent/ATE493129T1/en active
- 2002-10-29 EP EP02785330A patent/EP1441727B1/en not_active Expired - Lifetime
- 2002-10-29 ES ES02785330T patent/ES2358416T3/en not_active Expired - Lifetime
- 2002-10-30 US US10/283,989 patent/US7767230B2/en active Active
-
2005
- 2005-01-14 HK HK05100401.8A patent/HK1068263A1/en not_active IP Right Cessation
-
2010
- 2010-05-20 US US12/784,251 patent/US8815293B2/en not_active Expired - Lifetime
-
2011
- 2011-03-28 CY CY20111100327T patent/CY1111357T1/en unknown
- 2011-09-14 HK HK11109677.8A patent/HK1155381A1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE60238780D1 (en) | 2011-02-10 |
| WO2003037337A8 (en) | 2004-05-13 |
| EP1441727A1 (en) | 2004-08-04 |
| US7767230B2 (en) | 2010-08-03 |
| CY1111357T1 (en) | 2015-08-05 |
| CA2463158A1 (en) | 2003-05-08 |
| ATE493129T1 (en) | 2011-01-15 |
| HK1155381A1 (en) | 2012-05-18 |
| JP2005508975A (en) | 2005-04-07 |
| EP2295058A1 (en) | 2011-03-16 |
| CN101912367A (en) | 2010-12-15 |
| ES2436439T3 (en) | 2014-01-02 |
| EP1441727B1 (en) | 2010-12-29 |
| US8815293B2 (en) | 2014-08-26 |
| BRPI0213564B8 (en) | 2021-05-25 |
| ES2358416T3 (en) | 2011-05-10 |
| JP5067998B2 (en) | 2012-11-07 |
| US20030091645A1 (en) | 2003-05-15 |
| CN1578664A (en) | 2005-02-09 |
| EP2295058B1 (en) | 2013-09-04 |
| HK1068263A1 (en) | 2005-04-29 |
| BR0213564A (en) | 2004-08-31 |
| BRPI0213564B1 (en) | 2016-08-02 |
| US20100233217A1 (en) | 2010-09-16 |
| WO2003037337A1 (en) | 2003-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2463158C (en) | Depot formulations of iloperidone and a star polymer | |
| RU2464972C2 (en) | Composition with delayed release, including octreotide and two or more polylactide and glycolide copolymers | |
| KR101930588B1 (en) | An extended-release composition comprising a somatostatin derivative in microparticles | |
| EP1924242B1 (en) | Pharmaceutical composition comprising anastrozole | |
| KR20100110848A (en) | Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers | |
| MX2008015917A (en) | Sustained release formulations of aromatase inhibitors. | |
| US20190117573A1 (en) | Composition and method of preparation of risperidone extended release preparation | |
| BR122012031567B1 (en) | ILOPERIDONE DEPOSIT FORMULATIONS, MICROPARTMENT UNDERSTANDING ILOPERIDONE, AS WELL AS THEIR PREPARATION PROCESS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20221031 |